Zoetis (ZTS) Competitors $152.76 -3.64 (-2.33%) Closing price 03:59 PM EasternExtended Trading$154.84 +2.08 (+1.36%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ZTS vs. IDXX, MRK, PFE, BMY, RPRX, JAZZ, CORT, PRGO, SUPN, and PCRXShould you be buying Zoetis stock or one of its competitors? The main competitors of Zoetis include IDEXX Laboratories (IDXX), Merck & Co., Inc. (MRK), Pfizer (PFE), Bristol Myers Squibb (BMY), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Corcept Therapeutics (CORT), Perrigo (PRGO), Supernus Pharmaceuticals (SUPN), and Pacira BioSciences (PCRX). These companies are all part of the "medical" sector. Zoetis vs. Its Competitors IDEXX Laboratories Merck & Co., Inc. Pfizer Bristol Myers Squibb Royalty Pharma Jazz Pharmaceuticals Corcept Therapeutics Perrigo Supernus Pharmaceuticals Pacira BioSciences Zoetis (NYSE:ZTS) and IDEXX Laboratories (NASDAQ:IDXX) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk. Which has more volatility and risk, ZTS or IDXX? Zoetis has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500. Comparatively, IDEXX Laboratories has a beta of 1.56, meaning that its share price is 56% more volatile than the S&P 500. Is ZTS or IDXX more profitable? Zoetis has a net margin of 27.83% compared to IDEXX Laboratories' net margin of 24.41%. IDEXX Laboratories' return on equity of 64.42% beat Zoetis' return on equity.Company Net Margins Return on Equity Return on Assets Zoetis27.83% 56.90% 19.54% IDEXX Laboratories 24.41%64.42%29.89% Which has better valuation & earnings, ZTS or IDXX? Zoetis has higher revenue and earnings than IDEXX Laboratories. Zoetis is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZoetis$9.26B7.31$2.49B$5.8126.29IDEXX Laboratories$3.90B13.13$887.87M$12.0153.24 Do analysts recommend ZTS or IDXX? Zoetis presently has a consensus price target of $202.43, suggesting a potential upside of 32.51%. IDEXX Laboratories has a consensus price target of $649.44, suggesting a potential upside of 1.56%. Given Zoetis' higher possible upside, equities research analysts clearly believe Zoetis is more favorable than IDEXX Laboratories.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zoetis 0 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50IDEXX Laboratories 0 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.80 Do insiders and institutionals hold more shares of ZTS or IDXX? 92.8% of Zoetis shares are owned by institutional investors. Comparatively, 87.8% of IDEXX Laboratories shares are owned by institutional investors. 0.2% of Zoetis shares are owned by company insiders. Comparatively, 1.0% of IDEXX Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media favor ZTS or IDXX? In the previous week, Zoetis had 19 more articles in the media than IDEXX Laboratories. MarketBeat recorded 46 mentions for Zoetis and 27 mentions for IDEXX Laboratories. IDEXX Laboratories' average media sentiment score of 1.39 beat Zoetis' score of 1.31 indicating that IDEXX Laboratories is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zoetis 31 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IDEXX Laboratories 23 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryIDEXX Laboratories beats Zoetis on 11 of the 17 factors compared between the two stocks. Get Zoetis News Delivered to You Automatically Sign up to receive the latest news and ratings for ZTS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZTS vs. The Competition Export to ExcelMetricZoetisMED IndustryMedical SectorNYSE ExchangeMarket Cap$69.31B$2.51B$5.75B$21.39BDividend Yield1.28%48.51%6.66%3.49%P/E Ratio26.295.2862.2626.57Price / Sales7.31720.03537.3450.03Price / Cash22.1226.3325.7018.29Price / Book13.606.8111.195.30Net Income$2.49B$32.94M$3.28B$997.87M7 Day Performance-1.52%0.25%0.15%-0.01%1 Month Performance3.64%7.31%8.34%6.50%1 Year Performance-16.75%-2.92%54.21%11.34% Zoetis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZTSZoetis4.8645 of 5 stars$152.76-2.3%$202.43+32.5%-14.7%$69.31B$9.26B26.2913,800Positive NewsIDXXIDEXX Laboratories4.6677 of 5 stars$641.35-0.7%$649.44+1.3%+34.4%$51.31B$3.90B53.4011,000Positive NewsShort Interest ↓MRKMerck & Co., Inc.4.9971 of 5 stars$85.43-2.2%$107.44+25.8%-29.0%$213.39B$63.62B13.1675,000Positive NewsPFEPfizer4.8049 of 5 stars$25.15-2.8%$28.12+11.8%-14.7%$142.99B$63.63B13.3881,000Trending NewsBMYBristol Myers Squibb4.5528 of 5 stars$47.15-1.6%$56.38+19.6%-5.6%$95.97B$48.30B19.0134,100Positive NewsRPRXRoyalty Pharma4.9809 of 5 stars$35.99-0.9%$48.00+33.4%+23.9%$20.99B$2.26B20.8080News CoveragePositive NewsAnalyst UpgradeJAZZJazz Pharmaceuticals4.6388 of 5 stars$124.59+1.2%$181.43+45.6%+10.1%$7.56B$4.07B-18.512,800Positive NewsCORTCorcept Therapeutics4.9048 of 5 stars$68.82-2.1%$134.50+95.4%+97.5%$7.25B$716.08M60.90300Positive NewsPRGOPerrigo4.8807 of 5 stars$23.82-2.8%$33.00+38.6%-18.3%$3.28B$4.37B-41.068,379Analyst RevisionSUPNSupernus Pharmaceuticals3.0027 of 5 stars$44.43-1.0%$41.00-7.7%+28.3%$2.49B$665.13M38.63580PCRXPacira BioSciences3.086 of 5 stars$25.36-1.9%$30.83+21.6%+71.4%$1.14B$705.85M-9.12720News CoveragePositive News Related Companies and Tools Related Companies IDEXX Laboratories Alternatives Merck & Co., Inc. Alternatives Pfizer Alternatives Bristol Myers Squibb Alternatives Royalty Pharma Alternatives Jazz Pharmaceuticals Alternatives Corcept Therapeutics Alternatives Perrigo Alternatives Supernus Pharmaceuticals Alternatives Pacira BioSciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ZTS) was last updated on 9/2/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredDid you spot this in the Oval Office last week?When Tim Cook stood in the Oval Office last week, all eyes were on the "unique 24K gold gift" he presented to ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zoetis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zoetis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ZTS Stock Alerts